Antibiotic Prophylaxis for Ravulizumab
All patients receiving ravulizumab must receive quadrivalent meningococcal A, C, W, Y vaccination and antibiotic prophylaxis to prevent life-threatening meningococcal infections, as C5 inhibition blocks the terminal complement pathway required for defense against Neisseria meningitidis 1.
Vaccination Requirements
Patients should receive meningococcal vaccination as soon as possible before initiating ravulizumab therapy 1. The specific vaccine required is:
- Quadrivalent meningococcal A, C, W, Y vaccine (mandatory)
- Consider Serogroup B meningococcal vaccine as well, though the guideline specifically emphasizes the quadrivalent vaccine 1
Important Caveat on Vaccination Timing
Immunosuppression can impair vaccine response 1. Therefore, vaccination should ideally occur before immunosuppressive therapy when possible, though this must be balanced against the urgency of starting ravulizumab treatment.
Antibiotic Prophylaxis Regimen
While the specific antibiotic regimen and duration are not explicitly detailed in the provided evidence, the guideline emphasizes that prophylactic antibiotic prevention strategies are essential alongside vaccination to reduce the frequency of meningococcal infections 2.
Standard Approach (Based on Clinical Practice with C5 Inhibitors)
The typical prophylaxis regimen includes:
- Penicillin-based antibiotics (e.g., penicillin V or amoxicillin) as first-line
- Macrolides (e.g., azithromycin) for penicillin-allergic patients
- Duration: Throughout the entire treatment period with ravulizumab
Critical Monitoring
Patients must be educated about meningococcal infection warning signs and instructed to seek immediate medical attention for:
- Fever
- Headache
- Neck stiffness
- Altered mental status
- Rash
The risk of invasive meningococcal disease is the most feared adverse effect of anti-C5 therapy, though its frequency remains low when proper prophylactic strategies are implemented 2.
Special Populations
Patients of Chinese and/or Japanese descent may carry C5 gene polymorphisms (c.2654 G→A, c.2653 C→T) that confer resistance to anti-C5 monoclonal antibodies, making ravulizumab potentially ineffective in these individuals 1.